WO2005094814A1 - 外用剤 - Google Patents
外用剤 Download PDFInfo
- Publication number
- WO2005094814A1 WO2005094814A1 PCT/JP2005/006038 JP2005006038W WO2005094814A1 WO 2005094814 A1 WO2005094814 A1 WO 2005094814A1 JP 2005006038 W JP2005006038 W JP 2005006038W WO 2005094814 A1 WO2005094814 A1 WO 2005094814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- mass
- monoterpene
- parts
- external preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an external preparation containing a statin or a salt thereof having excellent transdermal absorbability as an active ingredient.
- Statins such as pitapastatin and pravastatin have excellent HMG-CoA reductase inhibitory activity, and are used to treat hyperlipidemia (Patent Documents 1 and 2) and Alzheimer's disease (Patent Documents 3 to 5).
- HMG_CoA reductase inhibitors include acne, psoriasis, dandruff (Patent Documents 7 and 8), hair growth suppression (Patent Document 9), and prevention of skin aging (Patent Documents 10 and 11). It is known to be useful as a local effect, and its development as an external preparation has been required.
- Patent Document 1 U.S. Patent No. 5,856,336
- Patent Document 2 US Patent No. 4,346,227
- Patent Document 3 U.S. Patent No. 6,080,778
- Patent Document 4 U.S. Patent No. 6,472,421
- Patent Document 5 U.S. Patent No. 6,511,800
- Patent Document 6 U.S. Patent No. 6,022,887
- Patent Document 7 U.S. Patent No. 5,730,992
- Patent Document 8 U.S. Patent No. 6,126,947 Patent Document 9: U.S. Patent No. 5,840,752
- Patent Document 10 U.S. Patent No. 5,733,558
- Patent Document 11 U.S. Patent No. 5,902,805
- An object of the present invention is to provide an external preparation having excellent transdermal absorbability, which contains statins or salts thereof as an active ingredient.
- the present inventors have conducted intensive studies to obtain an external preparation having excellent percutaneous absorbability containing statins or salts thereof. As a result, the following general formula (HMG-CoA reductase inhibitor) The present inventors have found that an external preparation having excellent percutaneous absorbability can be obtained by combining a compound represented by 1) with a monoterpene, and completed the present invention.
- the present invention provides the following components (A) and (B):
- R 1 represents an organic residue having a cyclic structure which may have a substituent
- R 2 represents a hydrogen atom or a lower alkyl group
- X represents an ethylene group or an etylene group .
- R 1 represents an organic residue having a cyclic structure which may have a substituent
- R 2 represents a hydrogen atom or a lower alkyl group
- X represents an ethylene group or an etylene group .
- the present invention provides an external preparation containing:
- the external preparation of the present invention containing the compound represented by the general formula (1) or a salt thereof and a monoterpene has excellent transdermal absorbability.
- the compound represented by the general formula (1) or a salt thereof used in the present invention is a compound known as an HMG_CoA reductase inhibitor useful as a therapeutic drug for hyperlipidemia.
- Examples of the organic residue having a cyclic structure represented by R 1 in the general formula (1) include an indolyl group, an indul group, a pyridinole group, a pyridol pyridyl group, a pyrazol pyridyl group, a thienopyridinole group, a pyrimidyl group, and a pyrazolyl group.
- pyrrolyl group imidazolyl group, indolizinole group, quinolyl group, naphthyl group, hexahydronaphthyl group, cyclohexyl group, phenylsilylphenyl group, phenylenyl group and phenylfuryl group, and hexahydronaphthyl group.
- An indolyl group, a pyridinole group, a pyrimidyl group, a pyrrolyl group and a quinolyl group are particularly preferred.
- Examples of the substituent which the organic residue may have include a hydroxy group, an alkyl group, an alkyloxyalkyl group, an alkylcarbonyloxy group, an anolexynoleamino group, an alkylsulfonylamino group, a phenylsulfonylamino group. And a carbamoyl group which may be substituted with an alkyl group or a phenyl group, an unsubstituted phenyl group, a halognophenyl group, an alkylphenyl group, an alkoxyphenyl group, and an oxo group.
- alkyl group alkyloxyalkyl group, alkylcarbonyloxy group, alkylamino group, alkylsulfonylamino group, phenylsulfonylamino group, alkylcaptamyl group, phenylcarbamoyl group, unsubstituted group Phenyl, halognophenyl, alkylphenyl and alkoxyphenyl groups are preferred.
- the alkyl group may be linear, branched or cyclic, and preferably has the following carbon number:! -6, particularly preferably! -4.
- alkyl group examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group. And the like.
- the alkyloxyalkyl group preferably has 2 to 7 carbon atoms, and includes a methoxymethyl group, a methoxyethyl group, an ethoxymethyl group, an ethoxyshethyl group and the like.
- Examples of the alkylcarbonyloxy group include an acetyloxy group, an isobutylcarbonyloxy group, and a pivaloyloxy group.
- Examples of the alkylamino group include a methinoreamino group and an ethylamino group.
- Examples of the alkylsulfonylamino group include methylsulfonylamino group, ethylsulfonylamino group, N-methyl-N-methylsulfonylamino group. And the like.
- Examples of the alkylcarbamoyl group include a methylcarbamoyl group and an ethylcarbamoyl group.
- Examples of the halognophenyl group include a chlorophenyl group, a fluorophenyl group, a bromophenyl group, an odophenyl group, and the like.
- Examples of the alkylphenyl group include a methylphenyl group and an ethylphenyl group.
- Examples of the alkoxyphenyl group include a methoxyphenyl group and an ethoxyphenyl group.
- the substitution position of the halogen atom, the alkyl group or the alkoxy group on the phenyl group is not particularly limited, but the p-position is preferred.
- an isopropyl group, a cyclopropyl group or a p- fluorophenyl group are preferred especially.
- the lower alkyl group represented by R 2 means an alkyl group having 1 to 6 carbon atoms, such as those described above.
- the salt of the compound represented by the general formula (1) is not particularly limited as long as it is a physiologically acceptable salt.
- an alkali metal salt such as a sodium salt and a potassium salt; Examples thereof include alkaline earth metal salts such as calcium salts and magnesium salts, organic amine salts such as phenethylamine salts, and ammonium salts.
- alkaline earth metal salts such as calcium salts and magnesium salts, organic amine salts such as phenethylamine salts, and ammonium salts.
- calcium salts which are preferably sodium or calcium salts, are particularly preferred.
- Compounds represented by the general formula (1) include, for example, US Pat. No. 4,739,073, European Patent Application Publication Nos. 114,027, 367,895, and US Pat. No. 4, 001, 255, No. 4, 613, 610, No. 4, 851, 427, No. 4, 755, 606, No. 4, 808, 607, No. 4, 751, 235 Nos. 4,939,159, 4,822,799, 4,804,679, 4,876,280, 4,829,081, 4,829 Nos. 4,927,851 and 4,588,715, FG Kathawala, Medical Research Review s, 11, 121-146 (1991), European Patent Application Publication Nos. 304, 063, 330 U.S. Pat.
- ronostatin (+)-(IS, 3R, 7S, 8S, 8aR) _1, 2, 3, 7, 8, 8a—hexahydro-1,3,7—dimethyl-1-8— [2 — [(2R, 4R) -tetrahydro-1-hydroxy-6_oxo-12H-pyran_2_yl] ethyl] _1_naphthinole (S) _2_methylbutyrate: US Patent No.
- cerivastatin ( (3R, 5S) —Eris mouth _ (E) _7_ [4- (4-Fluorophenyl) -2,6-diisopropyl-1-5-methoxymethyl-pyridine-13-yl] _3,5-Dihydroxy_6_heptenoic acid : U.S. Patent No.
- Rospastatin (7- [4- (4-fluorophenyl) _6_isopropyl-12- (N-methyl-1N-methanesulfonylaminopyrimidine) -1-5-yl]-(3R, 5S) —Dihydroxy— (E) _ 6 _heptenoic acid: U.S. Pat. No. 5,260,440, Japanese Patent No. 2,648,897; pitapastatin ((3R, 5S, 6E) -7 — [2 cyclop Mouth pill_4_ (4_fluorophenyl) _3_quinolyl] _3,5-dihydroxy_6_heptenoic acid: U.S. Patent No.
- the content of the compound represented by the general formula (1) or a salt thereof is preferably 0.001 to 20% by mass, more preferably 0.01 to 10% by mass, .:! To 5% by mass is particularly preferred.
- H CH 2
- those having an oxygen atom are preferred, and those having an oxygen atom are preferred.
- compounds having no oxygen atom for example, hydrocarbon monoterpene compounds.
- compounds having an oxygen atom include, for example, monoterpene having a hydroxyl group, monoterpene having an aldehyde group, monoterpene having a ketone group, and oxide group. And monoterpenes having a carboxyl group. Monoterpenes having a hydroxyl group or monoterpenes having an aldehyde group are more preferable.
- the monoterpenes are preferably a structural monoterpene, a monocyclic monoterpene, a monocyclic monoterpene, a bicyclic monoterpene, a modified monoterpene, or the like, which can be classified into a linear monoterpene or a monocyclic monoterpene. .
- linear monoterpene, monocyclic monoterpene, bicyclic monoterpene, and modified monoterpene include hydroxyl groups such as citronellol, nerol, geraniol, linalool, lilac alcohol, and nerolidol.
- a chain monoterpene having an aldehyde group such as citronellal and citral; a chain monoterpene having a ketone group such as perilaketone, ersioyl dioketone, and tagetone; a chain having an oxoxide group such as roseoxide.
- Linear monoterpenes having a carboxyl group such as citronellic acid; hydrocarbon-based linear monoterpenes such as minorecene and ocimene;
- Monocyclic monoterpenes having a hydroxyl group such as menthol, terpineol, thymol, fulvalol, grangeol, eugenol, and carveol; picrocrocin, perili
- Monocyclic monoterpenes having an aldehyde group such as aldehyde, irididal, neptalactone, cyclocitral, safranal, ferrandral, naucredal; menthon, carbomentone, p menthan _8-thiol _3_one, netaratatone
- a monocyclic monoterpene having a ketone group such as iridominolemesin, naucredal, caron, ylon, chonone, carbotanacetone, piperitenone; a monocyclic monoterpene having an oxide group such as lineatein, cineol, pinorele, and ascaridol; Hydrocarbon-based
- Bicyclic monoterpenes having a hydroxyl group such as borneol, paeoniflorin, pinocalveol, pinocampeol, and twillalcol; butyon, amberlon, caren-3-one 2-one, verbenone, Bicyclic monoterpene having a ketone group such as camphor; bicyclic monoterpene having an oxoxide group such as tali santenol o- ⁇ D darcoviranoside; hydrocarbon-based bicyclic monoterpene such as jidene, kalen, binene and sabinene Terpene;
- Modified monoterpenes having a hydroxyl group such as fentyl alcohol and nosygic alcohol
- Modified monoterpenes having a ketone group such as fenchone and santenone
- Modified monoterpenes having an ester group such as firifolid
- other hydrocarbon-based modified monoterpenes such as fentyl alcohol and nosygic alcohol
- a chain monoterpene having an aldehyde group or a monocyclic monoterpene having a hydroxyl group is more preferable.
- a chain monoterpene having an aldehyde group citronellal is particularly preferred, and as a monocyclic monoterpene having a hydroxyl group, menthol or terpineol is particularly preferred, menthol is most preferred.
- essential oils containing terpene include, for example, ylang-ylang oil (eg, containing eugenol and linalool), rose oil (eg, containing citronellol, geraniol, and nerol), neroli oil (eg, containing linalool), and cinnamon oil (eg, Eugenol), Jasmine oil (eg, containing linalool), Lemon oil (eg, containing limonene, geraniol, citral, linalool), Bergamot oil (eg, containing limonene), Lime oil (eg, containing limonene, citral) , Citronella oil (eg, containing citronellal, geraniol, citronellol), lemongrass oil (eg, containing citral), peppermint oil (eg, Oil, menthol, menthol, spearmint oil (eg, limonene), hinoki oil (eg,
- the content of monoterpenes during the total amount of the external preparation of the present invention 0. 01: is preferably 15% by mass, 0.1 01: 10 by mass 0/0 and more preferably tool 0. 1: 10 mass 0/0 is particularly preferred Les,. If the content of monoterpenes is less than 0.01% by mass, the transdermal absorbability of the compound represented by the general formula (1) may not be improved, and if it exceeds 15% by mass, skin irritation may occur.
- saturated fatty acids such as stearic acid, unsaturated fatty acids such as oleic acid, esters such as diisopropyl adipate, surfactants such as sorbitan monooleate, and keratin softeners such as urea are used.
- a fatty acid salt such as magnesium stearate, a cyclic polysaccharide such as a-cyclodextrin, an amine such as diphenylamine, an amino acid such as L-arginic acid, and a ketone such as crotamiton. No improvement was noted.
- Water is contained in the external preparation of the present invention in a balanced amount.
- the content is preferably 0.0 to 90% by mass in the total amount of the external preparation:! To 80% by mass is more preferable 10 to 70% by mass is particularly preferable.
- the pH of the external preparation of the present invention is preferably 6 to 10, more preferably 6 to 9 force S, and particularly preferably 6 to 8.5.
- optional components usually used in pharmaceutical compositions can be added as long as the effects of the present invention are not impaired.
- optional components include a solvent, a water-soluble polymer, a surfactant, a stabilizer, a pH adjuster, a crosslinking agent, a pressure-sensitive adhesive, a tackifier, a plasticizer, and a base.
- the solvent include monohydric alcohols such as benzyl alcohol, stearyl alcohol, and oleyl alcohol, concentrated glycerin, polyethylene glycol, 1,3-butylene glycol, 2-ethyl-1,3-hexanediol, and polypropylene.
- polyhydric alcohols such as glycol 2000.
- water-soluble polymer examples include celluloses such as hydroxyethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose, polysaccharides such as sucrose, sugar alcohols such as sorbitol and mannitol, polybutyl alcohol, and polybutyl. And synthetic polymers such as pyrrolidone.
- surfactant examples include anionic surfactants such as calcium stearate, magnesium stearate, and sodium laurinole sulfate, salt benzanolecone, benzeonite chloride, and cetyl pyridinine salt. Glyceryl monostearate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene alkyl ether, etc. Nonionic surfactants are included.
- the stabilizing agent examples include phenolic compounds such as methyl parabenzoate and propyl paraoxybenzoate, neutral compounds such as chlorobutanol and phenylethyl alcohol, inverted soaps such as benzalkonium chloride and benzethonium chloride, and butyl.
- antioxidants such as hydroxyethanol, tocopherol acetate, propyl gallate, and 2-mercaptobenzimidazole
- reducing agents such as ascorbic acid, sodium bisulfite, and sodium thiosulfate
- chelating agents such as lecithin and EDTA.
- Examples of the pH adjuster include phosphoric acid, boric acid, acetic acid, lactic acid, succinic acid, citric acid, tartaric acid, phthalic acid, salts of such alkali metals, triethanolamine, diethanolamine, diisopropanol. Amine, glycine, sodium hydroxide and the like. Furthermore, Britton-Robinson buffer, Clark-Lubs Buffer, Kolthoff Buffer, etc. may be used.
- crosslinking agent examples include magnesium chloride, calcium chloride, aluminum chloride, magnesium oxide, calcium oxide, aluminum oxide, potassium alum, dried aluminum hydroxide gel, calcium phosphate, magnesium phosphate, aluminum phosphate, and calcium citrate.
- examples include shim, aluminum acetate, aluminum glycinate, hydrous aluminum silicate, magnesium aluminate metasilicate, aluminum lactate, and synthetic hydrotalcite.
- the adhesive examples include partially neutralized polyacrylic acid, polyacrylic acid or a salt thereof, carboxymethyl cellulose or a salt thereof, styrene 'isoprene' styrene block copolymer, polyisobutylene, isoprene rubber, styrene 'butadiene' styrene Copolymer, acrylic polymer (copolymer of two or more selected from 2-ethylhexyl acrylate, butyl acetate, ethyl acrylate, ethyl methacrylate, methoxyethyl acrylate, and acrylic acid), dimethyl
- examples include polysiloxane.
- tackifier examples include polyterpene resin-based, petroleum resin-based, rosin-based, rosin ester-based, and oil-soluble phenol resin-based tackifiers.
- plasticizer examples include liquid paraffin, squalane and the like.
- Examples of the base include sodium alginate, polyethylene oxide, carboxymethyl cellulose, xanthan gum, gum arabic, trant gum, carboxybutyl polymer, gelatin, starch, kaolin, titanium oxide and the like.
- the form of the present invention is not limited as long as it is an external preparation, and examples thereof include a liquid preparation, a gel preparation, a creamy IJ, a lotion preparation, a spray preparation, an ointment preparation, a poultice preparation and a plaster preparation. .
- a liquid preparation of the present invention was obtained in the same manner as in Example 1, except that the amount of L-menthol was changed to 5 parts by mass.
- a liquid preparation of the present invention was obtained in the same manner as in Example 3, except that terbineol was replaced with citronellal (3,7-dimethyl-6-otatenal; manufactured by Wako Pure Chemical Industries, Ltd.).
- a liquid preparation of the present invention was obtained in the same manner as in Example 1 except that pitavastatin calcium was changed to pravastatin sodium.
- a liquid preparation was obtained in the same manner as in Example 1 except that menthol was not blended.
- a liquid preparation was obtained in the same manner as in Example 3 except that terbineol was replaced with L-arginine (L-arginine; manufactured by Kanto Chemical Co., Ltd.) and the amount of phosphoric acid was changed to 1.26 parts by mass.
- L-arginine L-arginine; manufactured by Kanto Chemical Co., Ltd.
- a liquid preparation was obtained in the same manner as in Example 5, except that L-menthol was not added.
- the skin permeability of the prepared liquid preparation was measured by the following method.
- the prepared solution was used as a donor solution, and a Britton-Robinson buffer (pH 7) was used as a receptor solution.
- the permeable membrane used was the abdominal skin of a Wistar rat (male, 8 weeks old).
- the skin surface was placed on the permeation part of a vertical diffusion cell (Franz cell) with the donor side facing the side, and filled with 1 mL of donor solution and 30 mL of receptor solution.
- the permeation experiment was performed while maintaining the vertical diffusion cell at a constant temperature (32 ° C.).
- the donor cell and sampling port were covered with a film (PARAFILM; American National Can) to prevent evaporation of water. Every 2 hours, 0.5 mL of the receptor solution was sampled from sampling rockers and 0.5 mL of a new receptor solution was replenished.
- Pravastatin was quantified.
- Permeability coefficient (cm / h) steady state flux (gZm 2 'h) / donor drug concentration (
- liquid formulation of the present invention containing L-menthol (Examples 1 and 2), terbineol (Example 3) and citronellal (Example 4), L-menthol with high skin permeability of pitapastatin calcium was added.
- Stearic acid (Comparative Example 2), oleic acid (Comparative Example 3), diisopropyl adipate (Comparative Example 4), and sorbitan monooleate (Comparative Example 5) in place of the strong liquid (Comparative Example 1) and L-menthol Urea (Comparative Example 6), magnesium stearate (Comparative Example 7), a-cyclodextrin (Comparative Example 8), diphenylamine (Comparative Example 9), L-arginine (Comparative Example 10), crotamiton (Comparative Example 11) ), The skin permeability was low in all cases.
- liquid preparation of the present invention containing L_menthol (Examples 5 and 6), L-menthol having high skin permeability of atorvastatin calcium or pravastatin sodium was used.
- the skin permeability was low.
- the plaster was spread between the nonwoven fabric and the liner using a spreading machine (manufactured by Ikeda Machinery) to a thickness of lmm to produce the poultice of the present invention.
- a poultice of the present invention was produced in the same manner as in Example 7, except that pitavastatin calcium was replaced with atorvastatin calcium and the amount was 0.1 parts by mass.
- a poultice was produced in the same manner as in Example 7 except that L-menthol was not blended.
- a poultice was produced in the same manner as in Example 8 except that L-menthol was not blended.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05727909A EP1731147A4 (en) | 2004-03-31 | 2005-03-30 | EXTERNAL PREPARATION |
US10/589,247 US20070166360A1 (en) | 2004-03-31 | 2005-03-30 | External preparation |
JP2006511711A JPWO2005094814A1 (ja) | 2004-03-31 | 2005-03-30 | 外用剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55768704P | 2004-03-31 | 2004-03-31 | |
US60/557,687 | 2004-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094814A1 true WO2005094814A1 (ja) | 2005-10-13 |
Family
ID=35063495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006038 WO2005094814A1 (ja) | 2004-03-31 | 2005-03-30 | 外用剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070166360A1 (ja) |
EP (1) | EP1731147A4 (ja) |
JP (1) | JPWO2005094814A1 (ja) |
KR (1) | KR20060135826A (ja) |
CN (1) | CN1938012A (ja) |
TW (1) | TWI345464B (ja) |
WO (1) | WO2005094814A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010126478A (ja) * | 2008-11-27 | 2010-06-10 | Kowa Co | 貼付剤 |
KR101408500B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 안정화된 도네페질 함유 접착 제제 |
JP2020121938A (ja) * | 2019-01-30 | 2020-08-13 | 国立大学法人九州大学 | 水溶性有効成分の放出が制御された水含有経皮吸収組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
EP2098232B1 (en) * | 2006-12-01 | 2013-06-05 | Nitto Denko Corporation | Percutaneous absorption preparation |
DE102006058623A1 (de) * | 2006-12-08 | 2008-06-12 | Bayer Cropscience Ag | Oxooxetane als fungizide Mittel |
CA2724502A1 (en) * | 2008-05-30 | 2009-12-03 | Nitto Denko Corporation | Adhesive preparation containing donepezil, and package of the same |
CN102046171B (zh) * | 2008-05-30 | 2013-06-19 | 日东电工株式会社 | 经皮吸收制剂 |
EP2473515A4 (en) | 2009-09-04 | 2013-11-27 | Univ Toledo | METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM |
CN103096881B (zh) * | 2010-03-03 | 2015-09-30 | 救急药品工业株式会社 | 含有具有不愉快味道的药物的膜制剂 |
US9044394B2 (en) * | 2010-10-18 | 2015-06-02 | PruGen IP Holdings, Inc. | Bioavailability enhancement delivery composition |
CN110090206A (zh) * | 2018-01-30 | 2019-08-06 | 日东电工株式会社 | 经皮吸收型制剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016682A1 (en) * | 1993-01-21 | 1994-08-04 | Yamanouchi Pharmaceutical Co., Ltd. | Novel, percutaneously absorbable preparation |
JPH09143062A (ja) * | 1995-11-21 | 1997-06-03 | Mikasa Seiyaku Kk | 経皮用粘着剤組成物及びその製法 |
JPH10505838A (ja) * | 1994-09-13 | 1998-06-09 | ラモツト・ユニバーシテイ・オーソリテイ・フオー・アプライド・リサーチ・アンド・インダストリアル・デベロツプメント・リミテツド | 皮膚疾患治療用組成物 |
JP2001507331A (ja) * | 1995-11-06 | 2001-06-05 | エルティエス ローマン テラピー−ズュステーメ アーゲー | 活性物質を皮膚へ経皮適用するための治療用調製剤 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
WO1991016044A1 (fr) * | 1990-04-24 | 1991-10-31 | Teijin Limited | Emplatre |
JPH04346922A (ja) * | 1991-05-24 | 1992-12-02 | Doujin Iyaku Kako Kk | 貼付剤 |
JP3086290B2 (ja) * | 1991-07-26 | 2000-09-11 | エスエス製薬株式会社 | ジクロフェナクナトリウム貼付剤 |
US5730992A (en) * | 1994-09-13 | 1998-03-24 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Compositions for the treatment of skin disorders |
EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
US5902805A (en) * | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
US6083979A (en) * | 1996-10-09 | 2000-07-04 | University Of Pittsburgh | Geranylgeraniol/lovastatin: a novel approach to blocking cancer transformation without cytotoxicity |
US5840752A (en) * | 1996-11-21 | 1998-11-24 | Henry; James P. | Reduction of hair growth |
DE69734832T2 (de) * | 1996-12-13 | 2006-08-31 | Zymogenetics, Inc., Seattle | Zusammensetzungen und verfahren zum stimulieren von knochenwachstum |
RU2179440C2 (ru) * | 1997-03-04 | 2002-02-20 | Висконсин Эламнай Рисерч Фаундэйшн | Композиция и способы подавления роста опухолевых клеток и опухоли с ее использованием |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
JP4275768B2 (ja) * | 1998-06-18 | 2009-06-10 | 久光製薬株式会社 | 水性粘着膏体 |
WO2000001384A1 (fr) * | 1998-07-01 | 2000-01-13 | Lead Chemical Co., Ltd. | Preparation a base de ketotifene destinee a etre absorbee par voie percutanee |
DE19830732B4 (de) * | 1998-07-09 | 2008-11-13 | Lts Lohmann Therapie-Systeme Ag | Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung |
IT1302638B1 (it) * | 1998-10-09 | 2000-09-29 | A C R Applied Coating Res Sa | Cerotti transdermici a base di cumarina o meliloto |
US6472421B1 (en) * | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
AU3536799A (en) * | 1999-04-26 | 2000-11-10 | Lead Chemical Co., Ltd. | Percutaneous preparations containing oxybutynin |
WO2001026688A1 (fr) * | 1999-10-15 | 2001-04-19 | Pola Chemical Industries Inc. | Promoteurs d'absorption percutanee pour electroporation |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
JP4138209B2 (ja) * | 2000-06-29 | 2008-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラバスタチン含有組成物 |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
JP2002332228A (ja) * | 2001-05-11 | 2002-11-22 | Yuutoku Yakuhin Kogyo Kk | 経皮吸収貼付剤およびその製造方法 |
JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
JP4088436B2 (ja) * | 2001-11-15 | 2008-05-21 | ロート製薬株式会社 | 皮膚外用剤 |
JP2003201217A (ja) * | 2001-12-28 | 2003-07-18 | Daizo:Kk | 頭髪用エアゾール組成物 |
EP1519751A2 (en) * | 2002-07-03 | 2005-04-06 | Esperion Therapeutics Inc. | Compositions comprising panthetine for the treatment of dyslipidemia |
JP4387639B2 (ja) * | 2002-07-16 | 2009-12-16 | 久光製薬株式会社 | 経皮吸収製剤 |
JP5027373B2 (ja) * | 2002-08-09 | 2012-09-19 | 帝國製薬株式会社 | エストラジオール含有貼付剤 |
WO2004014395A1 (ja) * | 2002-08-09 | 2004-02-19 | Teikoku Seiyaku Co.,Ltd. | 女性ホルモン含有貼付剤 |
EP1596832A2 (en) * | 2003-02-20 | 2005-11-23 | Teva Pharmaceutical Industries Ltd. | Menthol solutions of drugs |
US20050192340A1 (en) * | 2003-11-05 | 2005-09-01 | Moshe Flashner-Barak | Simvastatin formulations and methods of making same |
JP4579920B2 (ja) * | 2004-06-24 | 2010-11-10 | 興和株式会社 | アトルバスタチン外用剤組成物 |
-
2005
- 2005-03-30 US US10/589,247 patent/US20070166360A1/en not_active Abandoned
- 2005-03-30 JP JP2006511711A patent/JPWO2005094814A1/ja active Pending
- 2005-03-30 WO PCT/JP2005/006038 patent/WO2005094814A1/ja not_active Application Discontinuation
- 2005-03-30 EP EP05727909A patent/EP1731147A4/en not_active Withdrawn
- 2005-03-30 KR KR1020067019352A patent/KR20060135826A/ko not_active Application Discontinuation
- 2005-03-30 CN CNA2005800099374A patent/CN1938012A/zh active Pending
- 2005-03-31 TW TW094110334A patent/TWI345464B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016682A1 (en) * | 1993-01-21 | 1994-08-04 | Yamanouchi Pharmaceutical Co., Ltd. | Novel, percutaneously absorbable preparation |
JPH10505838A (ja) * | 1994-09-13 | 1998-06-09 | ラモツト・ユニバーシテイ・オーソリテイ・フオー・アプライド・リサーチ・アンド・インダストリアル・デベロツプメント・リミテツド | 皮膚疾患治療用組成物 |
JP2001507331A (ja) * | 1995-11-06 | 2001-06-05 | エルティエス ローマン テラピー−ズュステーメ アーゲー | 活性物質を皮膚へ経皮適用するための治療用調製剤 |
JPH09143062A (ja) * | 1995-11-21 | 1997-06-03 | Mikasa Seiyaku Kk | 経皮用粘着剤組成物及びその製法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1731147A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101408500B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 안정화된 도네페질 함유 접착 제제 |
JP2010126478A (ja) * | 2008-11-27 | 2010-06-10 | Kowa Co | 貼付剤 |
JP2020121938A (ja) * | 2019-01-30 | 2020-08-13 | 国立大学法人九州大学 | 水溶性有効成分の放出が制御された水含有経皮吸収組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1938012A (zh) | 2007-03-28 |
TWI345464B (en) | 2011-07-21 |
EP1731147A4 (en) | 2010-06-30 |
US20070166360A1 (en) | 2007-07-19 |
TW200600085A (en) | 2006-01-01 |
KR20060135826A (ko) | 2006-12-29 |
JPWO2005094814A1 (ja) | 2008-02-14 |
EP1731147A1 (en) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005094814A1 (ja) | 外用剤 | |
JP5475178B2 (ja) | 貼付剤 | |
WO2010103845A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
WO2010103844A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
JP5856424B2 (ja) | ロチゴチン含有経皮吸収型貼付剤 | |
ZA200506056B (en) | Formulation and methods for the treatment of thrombocythemia | |
JP2017061580A (ja) | ロピニロール含有貼付剤 | |
US10441551B2 (en) | Patch | |
JPWO2009031318A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
WO2010103843A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
KR101606950B1 (ko) | 케토프로펜리신염을 함유하는 수성 첩부제 | |
JP4579920B2 (ja) | アトルバスタチン外用剤組成物 | |
JP3226940B2 (ja) | 経皮投与製剤 | |
JP2010059058A (ja) | 鎮痛・抗炎症剤含有外用剤 | |
US20100239639A1 (en) | Medicated patch | |
AU2015329319B2 (en) | External preparation composition containing S-flurbiprofen | |
CN102076340B (zh) | 含芬太尼或其盐的经皮吸收型贴剂 | |
JP5308788B2 (ja) | 貼付剤 | |
JP2010006771A (ja) | 鎮痛・抗炎症剤含有外用剤 | |
JP2009280509A (ja) | 鎮痛・抗炎症剤含有外用剤 | |
JP4630065B2 (ja) | 外用剤 | |
JP4283507B2 (ja) | 経皮投与用貼付剤 | |
US20120052112A1 (en) | Risperidone-containing transdermal preparation and adhesive patch using same | |
JP2010053095A (ja) | 鎮痛・抗炎症剤含有外用剤 | |
KR100351088B1 (ko) | 비스테로이드성소염진통제의카타플라스마제조성물,그로부터제조되는카타플라스마제및그제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511711 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727909 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007166360 Country of ref document: US Ref document number: 10589247 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067019352 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580009937.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727909 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067019352 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10589247 Country of ref document: US |